Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Company Profile
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as multiple sclerosis (MS), lymphoma and rheumatoid arthritis. In 2008, Biogen Idec’s total revenues grew 29 percent over 2007 to $4.1 billion. Biogen Idec is headquartered in Cambridge, Massachusetts, with international headquarters in Zug, Switzerland. They have additional offices in the US, Canada, Australia, Japan and throughout Europe. Biogen Idec has a direct commercial presence in 29 markets, a network of distribution partners in more than 70 additional markets and operations in several new markets, including Central/Eastern Europe, Brazil, China and India.
Contact Info
Biogen Idec Brasil Produtos
Farmacêuticos Ltda.
Edifício Olimpia Trade
Av. Dr. Cardoso de Melo, 1.184,
17º andar,
Vila Olimpia- São Paulo-SP,
CEP; 04548-004
Brazil
Phone: +55 11 3568 3400
Fax: +55 11 3568 3440
www.biogenidec.com.br
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Allan Finkel, recently voted Novo Nordisk’s best GM globally, speaks about the partnerships and projects that the Brazilian affiliate organizes with doctors and patient associations to increase diabetes awareness in…
Roberto Alvarenga, general manager Latin America at Biotronik, the leading company globally for cardiovascular and endovascular medical technologies, documents how he has been leveraging on his long standing experience among…
Rolf Hoenger, president and general manager of Roche Pharma Brazil, provides an inspiring insight into the innovative and multi-faceted market access vision implemented by the Brazilian affiliate under his tenure…
Bruno Costa Gabriel, managing director of Janssen Brazil, provides insights into the transformative market approach successfully implemented by this leading company in Brazil and his main priorities to further leverage…
Pius Hornstein, MSc, PhD, country chair Sanofi Brazil and general manager Pharma, shares his positive outlook on the Brazilian pharma market over the next few years and details Sanofi’s strategy…
Laurena de Almeida Magnoni, regional director for Latin America at Besins Healthcare, a pharmaceutical company specialized in the development and worldwide diffusion of innovative drugs and food supplements for men’s…
Norberto Prestes, director of the Brazilian Pharmochemicals Manufacturers Association (ABIQUIFI), provides insights into the main dynamics that have been shaping Brazil’s pharmaceutical and API sectors over the past few years,…
Ricardo Lourenço, VP-Managing Director of Lupin in Brazil has been in charge of implementing the take over of Medquímica by Lupin. In this interview he explains Brazil is a land…
Josiel Florenzano, managing director of Lundbeck Brazil and South Cone, provides us with an overview of the main dynamics shaping the Brazilian CNS market as well as the opportunities he…
Neide Kawabata, president of B Braun Brazil, shares B Braun’s long track record of success and commitment to Brazil, the innovations they continue to bring to the market, and the…
Dr. Ogari Pacheco, president of the Board of Directors for Cristália, highlights the unique journey for Cristália over the past 45 years, as one of the most innovative local pharma…
Andrew Simpson, Scientific Director of Orygen, elaborates on the innovative collaboration model his company is taking part in to develop biotechnologies in Brazil, the importance of developing affordable treatments for…
See our Cookie Privacy Policy Here
